Amphista Therapeutics Analysis
What is Amphista Therapeutics?
Rationally designed Targeted Glue® technology for next-gen protein degradation therapies
Location
Cambridge, United Kingdom
Employees
51-200
Founded
2017
Product Features & Capabilities
- Targeted Glue® technology for targeted protein degradation
- Rationally designed degraders with enhanced tissue and indication scope
Use Cases
Develop therapies for diseases with high unmet need; Advance treatments for intractable conditions; Target pathogenic proteins in specific tissues; Design degraders with improved performance over traditional PROTACs; Expand therapeutic scope beyond current TPD limitations
Other Considerations
Founded by Advent Life Sciences; Built on science from Professor Alessio Ciulli's lab at University of Dundee; HQ in Cambridge, UK biopharma hub; Employee count 51-200; Founded in 2017
See something that needs updating? Suggest edits to this profile.
